[Effect of cellular immune supportive treatment on immunity of esophageal carcinoma patients after modern two-field lymph node dissection].
OBJECTIVE
Cellular immunity suppression is marked in patients with esophageal carcinoma, which may be resulted temporarily from surgical injury. This study was to evaluate the effect of cellular immune supportive treatment on cellular immunity of patients with esophageal carcinoma.


METHODS
A total of 60 patients with thoracic esophageal carcinoma, received two-field dissection, were randomized into control group and trial (immune supportive treatment) group. The patients in trial group were injected with Shenqi injection after operation; the patients in control group received no immune supportive treatment. Peripheral blood samples were obtained before operation, and 3 and 9 days after operation. AgNOR (argyrophilic nucleolar organizer regions) activity in peripheral blood T lymphocytes was measured by tumor immune microphotometry. T cell subsets were measured by flow cytometry.


RESULTS
The proportions of CD3+CD4+ and CD4+/CD8+ cells were significantly higher in trial group than in control group at 3 days after operation (P < 0.05). The amount of AgNOR and proportions of CD3+, CD3+CD4+, CD4+/CD8+, and CD4+CD25+ cells were significantly higher in trial group than in control group at 9 days after operation (P < 0.05). There was no significant difference in 1-year survival rate between the 2 groups (P > 0.05).


CONCLUSIONS
Shenqi injection could obviously improve cellular immunity of the esophageal carcinoma patients after modern two-field dissection.
Wang
Jun-Ye
JY
Skate Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P. R. China.
Ma
Guo-Wei
GW
Dai
Shu-Qin
SQ
Rong
Tie-Hua
TH
Wang
Xin
X
Lin
Peng
P
Ye
Wen-Feng
WF
Zhang
Lan-Jun
LJ
Li
Xiao-Dong
XD
Zhang
Xu
X
Yao
Guang-Yu
GY
D034961:Antigens, Nuclear / Q000097:blood; D027885:Astragalus propinquus / Q000737:chemistry; D017252:CD3 Complex / Q000097:blood; D015704:CD4 Antigens / Q000097:blood; D016516:CD4-CD8 Ratio; D016827:CD8 Antigens / Q000097:blood; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology*; D004938:Esophageal Neoplasms / Q000276:immunology* / Q000473:pathology* / Q000601:surgery; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007275:Injections, Intravenous; D053645:Interleukin-2 Receptor alpha Subunit / Q000097:blood; D008197:Lymph Node Excision / Q000379:methods; D008297:Male; D008875:Middle Aged; D005894:Panax / Q000737:chemistry; D010946:Plants, Medicinal / Q000737:chemistry; D011446:Prospective Studies; D015996:Survival Rate; D016176:T-Lymphocyte Subsets / Q000276:immunology*
D034961:Antigens, Nuclear; D017252:CD3 Complex; D015704:CD4 Antigens; D016827:CD8 Antigens; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; D053645:Interleukin-2 Receptor alpha Subunit; C051963:nucleolar organizer region associated proteins